Replimune Group, Inc. REPL
Set alert
17.61 USD +0.22 +1.27%
At close · Oct 30
17.53 -0.08 -0.45%
After hours · Oct 30, 7:30 PM ET
16.64 Day range 18.27
1.50 52-week range 18.27
- YTD
- +81.17%
- 1 year
- +71.80%
- Open
- 17.49
- Prev close
- 17.39
- Mkt cap
- 1.67B
- Vol
- 3.85M
- Avg vol
- 3.01M
- EPS
- -2.79
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 16.64
- High
- 18.27
- Forward P/E
- -27.19
- Beta
- 0.00
- Short ratio
- 11.50
- Inst. own
- 105.29%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 2, 2027
- 50-d avg
- 13.51
- 200-d avg
- 9.24
- 1y target
- 23.33
3M chart
Events in this range
- Jul 31, 2026Rating: Wedbush · Neutral → Neutral
- Aug 4, 2026Rating: Leerink Partners · Market Perform → Outperform
- Aug 7, 2026Rating: Wedbush · Neutral → Outperform
- Aug 7, 2026Rating: JP Morgan · Overweight → Overweight
- Aug 14, 2026Earnings: -0.72; estimate -0.694; surprise -3.75%
- Aug 26, 2026Rating: JP Morgan · Overweight → Overweight
- Oct 28, 2026Earnings: -0.54; estimate -0.784; surprise 31.12%
- Oct 29, 2026Rating: Leerink Partners · Outperform → Outperform
Signals (13)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| RSI: Overbought | Oct 28, 2026 | 4 days ago |
| SMA: Bullish | Oct 27, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 26, 2026 | 6 days ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 2 months ago |
| SMA: Bullish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 31, 2026 | 3 months ago |
Discussion (20)
Sign in to join the discussion
Mark REPL 2 months ago #1IOVA is king.
Mark REPL 2 months ago #2Sold and loaded the boat with IOVA shares. Good luck.
Mark REPL 3 months ago #3Wow that was close 10000 shares sold.
Mark REPL 3 months ago #4Sold the news leaked on Reddit.
Mark REPL 3 months ago #5Volume is low.. not good..
However, if Dr. Richard Pazdur returns to lead the FDA, the impact on Iovance Biotherapeutics (IOVA) is expected to be highly favorable, particularly for its long-term oncology pipeline.
A potential return of Dr. Richard Pazdur to the FDA is widely seen as bad news for REPL because he is historically the primary reason their melanoma drug was rejected.
$REPL @TILS KILLS CANCER ?? Today is Monday, dummy
$REPL ?? Oh SHIT! ? Its gonna take off
Today the Earnings Date for $REPL ???